CD79B Y196 mutation is a potent predictive marker for favorable response to R‐MPV in primary central nervous system lymphoma

BACKGROUND: Rituximab, high‐dose methotrexate (HD‐MTX), procarbazine and vincristine (R‐MPV), has significantly prolonged the survival of patients with primary central nervous system lymphoma (PCNSL), but predictive factors for response to R‐MPV have not yet been investigated. Herein, we investigate...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamaguchi, Junya, Ohka, Fumiharu, Lushun, Chalise, Motomura, Kazuya, Aoki, Kosuke, Takeuchi, Kazuhito, Nagata, Yuichi, Ito, Satoshi, Mizutani, Nobuhiko, Ohno, Masasuke, Suzaki, Noriyuki, Takasu, Syuntaro, Seki, Yukio, Kano, Takahisa, Wakabayashi, Kenichi, Oyama, Hirofumi, Kurahashi, Shingo, Tanahashi, Kuniaki, Hirano, Masaki, Shimizu, Hiroyuki, Kitano, Yotaro, Maeda, Sachi, Yamazaki, Shintaro, Wakabayashi, Toshihiko, Kondo, Yutaka, Natsume, Atsushi, Saito, Ryuta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067082/
https://www.ncbi.nlm.nih.gov/pubmed/36478416
http://dx.doi.org/10.1002/cam4.5512

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067082/
https://www.ncbi.nlm.nih.gov/pubmed/36478416
http://dx.doi.org/10.1002/cam4.5512

Ejemplares similares